A recent study in this journal 1 raised the issue of prolonged hypogammaglobulinemia in patients receiving autologous hematopoietic stem cell transplantation (HSCT) for highrisk B-cell lymphoma and maintenance therapy with rituximab. Despite significant hypogammaglobulinemia, these patients did not experience significant infectious complications. With the following case report, we aim to increase the awareness of the potential for severe infectious complications associated with the hypogammaglobulinemia observed in lymphoma patients given lymphocytotoxic chemotherapy in combination with rituximab before allogeneic HSCT.
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A 28-year-old man with diffuse large B-cell lymphoma (DLBCL) stage IIB in second refractory relapse was referred for an allogeneic HSCT from his HLA-identical sister. He had received primary treatment with eight cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and mediastinal radiotherapy (30 Gy). Three months later, pulmonary relapse was noted and the patient received two cycles of ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) and surgical tumor debulking. Postoperatively, four weekly doses of rituximab 375 mg/m 2 were administered. One week after the last rituximab dose, chemotherapy with BEAM (etoposide, carmustine, cytarabine, melphalan) for debulking was administered, followed by reduced intensity HSCT (fludarabine and 2 Gy total body irradiation) conditioning 1 month later. 3 GVHD prophylaxis included methotrexate and CyA. The patient developed acute GVHD of the skin (grade II) and gastrointestinal tract (grade III), overall grade III, which was steroid responsive. Possible pulmonary aspergillosis was treated with voriconazole. CMV reactivation was treated with ganciclovir. At day 100 post transplant, the patient was in complete remission with full donor chimerism, but developed extensive chronic GVHD of moderate severity.
Eight months post transplant, still immunosuppressed with CyA and prednisone 15 mg daily, the patient presented with joint pain, tender swelling and redness over the left elbow, subsequently migrating to other joints including hips, knees and hands, accompanied by generalized erythema without fever. Aspiration of the joint fluid revealed 26 Â 10 9 leukocytes/l (69% polymorphonuclear cells, 31% mononuclear cells), no crystals and no bacteria. Peripheral blood counts showed hemoglobin 78 g/l, reticu- /l) was now present in peripheral blood with complete B-cell aplasia on lymphocyte sub-population analysis, and agammaglobulinemia (IgG 0.39 g/l, IgM and IgA not detectable). Pretransplant immunoglobulin levels had been normal. A broader range of diagnostic tests was performed, including PCR from joint fluid for Mycoplasma spp, Ureaplasma spp, Borrelia burgdorferi, Mycobacterium tuberculosis, Enterovirus and Parvovirus B19. The treatment was empirically changed to doxycycline and intravenous immunoglobulin (IVIG) was started. PCR for U. urealyticum was positive, and septic polyarthritis due to U. urealyticum was diagnosed. His course was complicated by CMV-reactivation, RSV-pneumonitis and acute renal failure requiring hemodialysis. He received specific treatment for the infectious organisms identified, and recovered completely from arthritis and other complications. He remains in complete remission 4.5 years post transplant. IVIG substitution is still necessary owing to a persistent lack of immunoglobulin production, despite slow regeneration of normal B-lymphopoiesis. T-cell and NK-cell subpopulations are normal. The need for ongoing IVIG substitution was tested repeatedly every year, and confirmed by drops in IgG levels below 3 g/l and development of upper respiratory symptoms. No bronchiectasis has been detected on computed tomography scans to date.
This case is remarkable for several reasons. First, the combination of multiple lymphocytotoxic therapies described in our patient (intensive chemotherapy in combination with rituximab, intensive conditioning regimen including fludarabine and total body irradiation, allogeneic HSCT, GVHD and its treatment with corticosteroids) led to impaired immune reconstitution post transplant, which resulted in complete and long-lasting B-cell aplasia and agammaglobulinemia. Second, septic arthritis with U. urealyticum is an infection typically seen in patients with common variable immunodeficiency and hypogammaglobulinemia, 4 but to date has not been described in the post transplant setting. Differential diagnosis of post transplant polyarthritis includes infectious causes (viral, bacterial, fungal), parainfectious/reactive causes, crystal-induced arthritis, connective tissue diseases or alloreactivity (GVHD)/altered immunity post transplant. In our patient, both humoral and cellular immunodeficiency might have contributed to the development of this severe infection. Third, complete B-cell aplasia was disguised by a normal absolute lymphocyte count. Therefore, regular analysis of lymphocyte sub-populations and immunoglobulin levels should be incorporated into the post transplant follow-up of patients given lymphocytotoxic therapy.
Rituximab in combination with chemotherapy has become the gold standard for the treatment for DLBCL, 5 and indications for autologous or allogeneic HSCT for lymphoma patients have become broader. 6 In the nontransplant setting, B-cell lymphopenia is frequent after rituximab treatment and usually lasts 6-9 months, but hypo-and agammaglobulinemia and severe infections are rare. 7 In patients receiving autologous HSCT, hypogammaglobulinemia can be prolonged for up to 5 years.
1 Fatal infections are extremely rare, 2,8 although described for up to 12 months after rituximab in combination with chemotherapy or HSCT in lymphoma patients (Roche Pharma, personal communication 2007). From pharmacokinetic studies, it is known that rituximab is usually detected in the serum of patients in significant amounts for 3-6 months. 9 When rituximab is given in the peritransplant period, it is reasonable to hypothesize that the antibody is present in the circulation and interferes with, or delays, post transplant B-cell immune reconstitution. A recent study analyzed B-cell sub-populations in 17 lymphoma patients, 12-43 months after the last dose of rituximab. 10 They demonstrated a delayed recovery of memory B cells, a defect in expression of co-stimulatory molecules and impaired immunoglobulin production in vitro. With this report, we wish to increase physician awareness of impaired immune reconstitution of the B-cell compartment and associated possible infections in HSCT patients receiving lymphocytotoxic chemotherapies including rituximab. 
